As of 6 Nov 2026, Suven Life Sciences is loss-making on a trailing 12-month basis, with a net loss of ₹352 Cr, so it has no P/E ratio. The share price is ₹264.85, 34% below its 52-week high. Sales fell 19% a year over 3 years. It carries very little debt. It is a small-cap company with a market cap of ₹7,484 Cr, ranked 37th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 40% over the past year.
- ₹271.00
- ₹277.00
- ₹262.65
- ₹276.10
- 3.3 L
Health check
- ReturnsAhead
+39.9% over a year, better than 5 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −19.3% a year over 3 years.
- ProfitabilityNegative
ROCE -45.6% vs peer median 17.9%.
- Balance sheetStretched
Practically debt-free.
- Red flags4 to check
Loss-making over the last twelve months.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹7,484 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 11.81
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −78.8%
- Peers 14.7%
- ROCE
- −45.6%
- Peers 17.9%
- Debt to equity
- 0.03
- Debt ₹17 Cr
- EPS (TTM)
- −₹14.89
- Face value ₹1
- OPM (TTM)
- −4155.5%
- Net margin 0.0%
- Sales growth
- +91.0%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 849.09
- EV/EBITDA −17.7
Strengths and risks
Strengths
- Practically debt-free.
- Quarterly sales up 91.0% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −78.8%.
- 34% below its 52-week high.
- Interest coverage of only −1800.5×.
About Suven Life Sciences
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse…
- Headquarters
- Hyderabad
- Employees
- 142
- Sector
- Healthcare
- ISIN
- INE495B01038
- Website
- suven.com
Price range
- Avg volume (3M)
- 6.9 L
- 1-year return
- plus 39.9%
- From 52-week high
- minus 34.3%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| SUVENSuven Life Sciences | 264.85 | minus 4.07% | 7,484 | – | 11.81 | – | −66.4% | −4155.5% | −19.3% | – | 0.00% | plus 39.9% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 1.9 | 0.9 | 2.8 | 1.5 | 3.6 | |
| 52.6 | 80.7 | 106 | 52.2 | 136 | |
| −50.7 | −79.8 | −103 | −50.6 | −133 | |
| −2718.6% | −8678.3% | −3679.7% | −3330.9% | −3715.9% | |
| 0.6 | 3.8 | 2.8 | 6.8 | 7.5 | |
| – | – | – | 0.2 | 0.5 | |
| 1.4 | 1.3 | 1.3 | 1.6 | 2.2 | |
| −51.5 | −77.3 | −102 | −45.6 | −128 | |
| −51.5 | −77.3 | −102 | −45.6 | −128 | |
| -2.36 | -3.48 | -4.55 | -2.02 | -4.84 |
Profit & loss
- Sales CAGR 3Y
- −19.3%
- ROE
- −78.8%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 13.5 | 11.7 | 6.7 | 7.1 | |
| – | minus 13.6% | minus 43.1% | +6.9% | |
| 140 | 140 | 173 | 291 | |
| −126 | −128 | −166 | −284 | |
| −931.3% | −1098.8% | −2493.2% | −3993.3% | |
| 6 | 16.4 | 5.6 | 4 | |
| 0.3 | 0.2 | 0 | 0.2 | |
| 5.8 | 5.8 | 5.3 | 5.6 | |
| 8 | 12 | 5 | 9.5 | |
| −118 | −106 | −161 | −276 | |
| – | 0.9% | – | – | |
| −118 | −105 | −161 | −276 | |
| -6.63 | -4.82 | -7.37 | -12.13 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 21.8 | 21.8 | 21.8 | 26.4 | |
| 354 | 248 | 88.2 | 565 | |
| 1.6 | 0.7 | – | 16.7 | |
| 12 | 14.2 | 25.2 | 16.1 | |
| 389 | 285 | 135 | 624 | |
| 37.1 | 28 | 59.5 | 76.5 | |
| 0.1 | 0 | 0 | 3.6 | |
| 100 | – | 0 | 0.9 | |
| 83.4 | 90.9 | 37.3 | 189 | |
| 168 | 166 | 38.3 | 354 | |
| 389 | 285 | 135 | 624 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −116 | −82.6 | −154 | −301 | |
| −248 | 61.6 | 155 | −462 | |
| 396 | −1.1 | −0.8 | 757 | |
| 31.7 | −22.1 | 0.1 | −6.7 | |
| −2.9 | – | −37.3 | −5.1 | |
| −119 | −82.6 | −191 | −306 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 1.3% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.